Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), a cell surface glycoprotein with a molecular weight of approximately 24.6 kDa, is a crucial player in regulating T cell responses. Belonging to the immunoglobulin superfamily, CTLA-4 acts primarily as a negative regulator, effectively dampening T cell activation. This inhibitory function is vital for maintaining immune homeostasis and preventing autoimmunity. By competing with the co-stimulatory molecule CD28 for binding to CD80/CD86 ligands on antigen-presenting cells (APCs), CTLA-4 limits T cell proliferation and cytokine production. This delicate balance of co-stimulation and co-inhibition is essential for a controlled immune response.
Leinco Technologies offers a comprehensive selection of highly validated CTLA-4 antibodies, trusted by researchers worldwide in areas such as immunotherapy, cancer research, and autoimmune disease studies.
- Immunotherapy: Targeting CTLA-4 has emerged as a powerful strategy in cancer immunotherapy, as blocking its inhibitory function can enhance anti-tumor T cell responses.
- Autoimmune diseases: Dysregulation of CTLA-4 can contribute to the development of autoimmune disorders, making it a target for therapeutic intervention.
- Cancer research: CTLA-4 plays a critical role in the tumor microenvironment and the modulation of anti-tumor immunity.
We are committed to providing you with the tools and resources you need to advance cancer biomarker research. Explore our catalog to find the perfect CTLA-4 antibody for your research needs.
